argenx SE (ARGX)
Nasdaq · American depositary receipt
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ARGX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ARGX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ARGX at a glance
Key statistics
$54.69B
Market capitalization
- Previous close
- $869.72
- Open
- $874.43
- Day range
- $873.84 – $887.74
- Volume
- 372.4K
- Average volume (30 sessions)
- 384.6K
- Shares outstanding
- 62.89M
- Beta (1 year, vs SPY)
- 0.39
Where the price sits in its year
52-week range
55% of the range
- Below the 52-week high
- -17.4%
- Above the 52-week low
- +33.9%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $891.70-2.5%
- 50-day average
- $952.15-8.7%
- 200-day average
- $851.45+2.1%
Between the conventional 30 and 70 bands.
+8.4%
1 week
-12.0%
1 month
+2.1%
3 months
+3.4%
Year to date
+3.1%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ARGX
ARGX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ARGX.
See the plans →
Every planScreen names like ARGX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ARGX
Put ARGX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ARGX
See whether there is an open premium alert on ARGX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ARGX headlines
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
GlobeNewswire Inc. · Oct 19, 2026
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
GlobeNewswire Inc. · Oct 15, 2026
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
GlobeNewswire Inc. · Sep 29, 2026
- argenx Completes Acquisition of Forte Biosciences, Inc.
GlobeNewswire Inc. · Aug 27, 2026
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
GlobeNewswire Inc. · Aug 6, 2026
- argenx to Host Autoimmune Myositis R&D Webinar
GlobeNewswire Inc. · Jun 23, 2026
- argenx to Present at Upcoming Investor Conferences
GlobeNewswire Inc. · May 27, 2026
- Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease
Benzinga · May 11, 2026
SEC Form 4, most recent first
Insider filings
No insider transactions reported for ARGX recently. ETFs and many foreign issuers do not file Form 4.
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
- Exchange
- Nasdaq
- Security
- American depositary receipt
- Employees
- 1,863
- Listed since
- May 18, 2017
- Website
- argenx.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.